<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000400003</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i4.1871</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia y caracterización de las enfermedades autoinmunitarias en pacientes mayores de 13 años en un hospital de Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence and characterization of autoimmune diseases in patients older than 13 years in a hospital of Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palmezano-Díaz]]></surname>
<given-names><![CDATA[Jorge Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa-Pineda]]></surname>
<given-names><![CDATA[Claudia Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Amaya]]></surname>
<given-names><![CDATA[Reynaldo Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Plazas-Rey]]></surname>
<given-names><![CDATA[Lisette Katherine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[Santander ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[Santander ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[Santander ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[Santander ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>4</numero>
<fpage>522</fpage>
<lpage>535</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000400003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES Las enfermedades autoinmunitarias afectan alrededor de 3 a 5% de los seres humanos, especialmente a las mujeres. Por su poca prevalencia se desconocen los datos clínicos locales del comportamiento de esta enfermedad.  OBJETIVO Encontrar la prevalencia de las enfermedades autoinmunitarias en el Hospital Universitario de Santander, Santander, Colombia, así como realizar la caracterización clínica y sociodemográfica de las enfermedades.  MATERIAL Y MÉTODO  Estudio observacional, descriptivo de corte transversal, retrospectivo de la prevalencia de enfermedades autoinmunitarias en el Hospital Universitario de Santander entre 2012 y 2016 en pacientes mayores de 13 años que ingresaron a la institución.  RESULTADOS Se encontraron 1463 enfermedades autoinmunitarias con prevalencia de 378 casos por cada 100,000 pacientes mayores de 13 años, atendidos en el Hospital Universitario de Santander y la población con enfermedad autoinmunitaria fue de 0.4%. Las enfermedades más prevalentes fueron la artritis reumatoide, psoriasis, enfermedad de Graves, púrpura trombocitopénica inmunitaria y lupus eritematoso sistémico y los órganos más afectados fueron la piel, la glándula tiroides, el sistema hematológico, el páncreas y el sistema nervioso.  CONCLUSIONES Los datos encontrados sugieren que la prevalencia en nuestro medio es similar a la de otras poblaciones; sin embargo, estas prevalencias son multifactoriales y pueden variar entre las diferentes poblaciones.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND Autoimmune diseases affect around 3-5% of human beings, especially women. Due to its low prevalence, local clinical data on the behavior of this disease are unknown.  OBJECTIVE To find the prevalence of autoimmune diseases in the University Hospital of Santander, as well as to carry out the clinical and sociodemographic characterization of the diseases.  MATERIAL AND METHOD  An observational, descriptive and retrospective cross-sectional study on the prevalence of autoimmune diseases was done at the University Hospital of Santander between 2012 and 2016 in patients over 13 years of age who entered to the institution.  RESULTS A total of 1463 autoimmune diseases were found, with a prevalence of 378 cases per 100,000 patients over 13 years of age treated at the University Hospital of Santander and the population with autoimmune disease was 0.4%. The most prevalent diseases were rheumatoid arthritis, psoriasis, Graves&#8217; disease, immune thrombocytopenic purpura and systemic lupus erythematosus and the most affected organs were the skin, thyroid gland, hematology system, pancreas and nervous system.  CONCLUSIONS The data suggest that the prevalence in our environment is similar to that of studies in other populations; however, these prevalences are multifactorial and may vary among different populations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedades autoinmunitarias]]></kwd>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[psoriasis]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de Graves]]></kwd>
<kwd lng="es"><![CDATA[púrpura trombocitopénica inmunitaria]]></kwd>
<kwd lng="es"><![CDATA[lupus eritematoso sistémico]]></kwd>
<kwd lng="en"><![CDATA[Autoimmune diseases]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Psoriasis]]></kwd>
<kwd lng="en"><![CDATA[Graves&#8217; disease]]></kwd>
<kwd lng="en"><![CDATA[Immune thrombocytopenic purpura]]></kwd>
<kwd lng="en"><![CDATA[Systemic lupus erythematosus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las enfermedades autoinmunes el rastreo de los hilos compartidos]]></article-title>
<source><![CDATA[Hosp Pract (1995)]]></source>
<year>1997</year>
<volume>32</volume>
<page-range>147</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diamond enfermedades autoinmunes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>340</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbuckle]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[McClain]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Rubertone]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desarrollo de autoanticuerpos antes de la aparición clínica de lupus eritematoso sistémico]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>1526</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los predictores de enfermedad autoinmune autoanticuerpos y más allá]]></article-title>
<source><![CDATA[Autoinmunidad]]></source>
<year>2008</year>
<volume>41</volume>
<page-range>419</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Stroehla]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of autoimmune diseases]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2003</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>119-25</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Gange]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[NMH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and estimated population burden of selected autoimmune diseases in the United States]]></article-title>
<source><![CDATA[Clin Immunol Immunopathol]]></source>
<year>1997</year>
<volume>84</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-43</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rees]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grainge]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lanyon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2017</year>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nasonov]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Soloviev]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lila]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Togizbayev]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan)]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2014</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>213-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alamanos]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Voulgari]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[Drosos]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria a systematic review]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2006</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>182-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abraham-Nordling]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Byström]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Törring]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lantz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Calissendorff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of hyperthyroidism in Sweden]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2011</year>
<volume>165</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>899-905</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diagne]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Faye]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ndao]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Djiba]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Ndongo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspects épidémiologique, clinique, thérapeutique et évolutif de la maladie de Basedow en Médecine Interne au CHU Ledantec Dakar (Sénégal)]]></article-title>
<source><![CDATA[Pan Afr Med J]]></source>
<year>2016</year>
<volume>25</volume>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peyerl]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TSI assay utilization Impact on costs of Graves' hyperthyroidism diagnosis]]></article-title>
<source><![CDATA[Am J Manag Care]]></source>
<year>2012</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
